Abstract: The present invention relates to a method for preparing Asenapine. In particular, the present invention relates to a method for preparing pharmaceutically acceptable Asenapine free base and new crystal form thereof, and also relates to methods for preparing the intermediate compounds used in said method.

Abstract: The present invention relates to an application of 5-bromo-2-(?-hydroxyamyl) sodium benzoate salt (BZP) in treatment of ischemic cardiovascular and cerebral vascular diseases, in particular to a BZP compound for treatment of ischemic stroke and a treatment method, and more specifically, relates to a treatment solution for treating mild and moderate acute ischemic stroke by using the BZP and a pharmaceutical composition comprising the BZP.

Abstract: A method for synthesis of Eliglustat and intermediate compounds thereof. Specifically, a method for synthesis of Eliglustat and pharmaceutically acceptable salts thereof, and further to intermediate compounds used in the method and a preparation method for the intermediate compounds. Compared with an existing synthesis method, the method for synthesis of Eliglustat of the present invention uses novel synthetic intermediates and synthesis steps, features ease of operation, high yield, good purity of intermediates and target products, etc., and facilitates industrial production.

Abstract: The present invention relates to a method for preparing Asenapine. In particular, the present invention relates to a method for preparing pharmaceutically acceptable Asenapine free base and new crystal form thereof, and also relates to methods for preparing the intermediate compounds used in said method.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention relates to nebivolol synthesis method and intermediate compound thereof. Specifically, the present invention relates to a method for synthesizing nebivolol, intermediate compound thereof, and a method for preparing the intermediate compound.

Abstract: The present invention relates to a compound of formula III, wherein, R is selected from the group consisting of C1-C4 alkyl, substituted or unsubstituted phenyl, and substituted or unsubstituted benzyl, preferably isopropyl; and two Ar groups may be the same or different, and are each independently selected from the group consisting of substituted or unsubstituted aryl groups, preferably substituted or unsubstituted phenyl, such as p-methoxyphenyl and the like, wherein the compound is preferably in a solid form.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention relates to a process for synthesis of Eliglustat and intermediate compounds thereof. In particular, the present invention belongs to the field of synthesis of organic compounds, relates to a process for synthesis of Eliglustat and pharmaceutically acceptable salts thereof, and relates to the intermediate compounds used in the process and a process for preparation of the intermediate compounds. Compared with the existing synthetic processes, the process for preparing Eliglustat according to the present invention utilizes novel intermediates and steps for synthesis, has advantages of convenient operations, high yield, good purity of intermediates and desired product, and it is easy to apply the process in the industrial production.

Abstract: The present invention relates to nebivolol synthesis method and intermediate compound thereof. Specifically, the present invention relates to a method for synthesizing nebivolol, intermediate compound thereof, and a method for preparing the intermediate compound.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention relates to a process for synthesis of Eliglustat and intermediate compounds thereof. In particular, the present invention relates to a process for synthesis of Eliglustat and pharmaceutically acceptable salts thereof, and relates to the intermediate compounds in the process and a process for preparation of the intermediate compounds.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention relates to a preparation method for a medicine and an intermediate compound thereof, specifically, relates to a preparation method for entecavir, an intermediate compound thereof, and a synthesis method for the intermediate compound.